Moxetumomab pasudotox

Observational studies Therapy-related adverse events to moxetumomab pasudotox were assessed in a phase I trial in 28 patients with relapsed/refractory hairy cell leukaemia. Three patients experienced serious adverse reactions two showed depressed platelet counts and the third hypoxia and bronchospasm. The most common adverse events were grade 1 to 2 hypoalbuminaemia and elevated aminotransferases. Other less often seen events included headache, hypotension, nausea, fatigue, weight gain and myalgia [173 ]. 

Kreitman RJ, Pastan 1. Antibody fusion proteins anti-CD22 recombinant immrmotoxin moxetumomab pasudotox. GHn Gancer Res 2011 17(20) 6398-405. 

Kreitman RJ, TaUman MS, Robak T, Goutre S, Wilson WH, Stetler-Stevenson M, et al. Phase 1 trial of anti-CD22 recombinant immrmotoxin moxetumomab pasudotox (GAT-8015 or HA22) inpatients with hairy cell leukemia. J Clin Oncol 2012 30(15) 822-8. 

---